Table 3.
LC50 comparisons (cell survival; clonogenic assays) for PARPis in cell lines with down-regulated BRCA1.
| LC50 (µM) | |||
|---|---|---|---|
| AS | BRCA1 si#13 (fold change) | BRCA1 si#14 (fold change ^) | |
| PARPi | |||
| A2780 BRCA1 KD (cell viability) | |||
| olaparib | 1.2330 | 0.1994 (6.18) | 0.3539 (3.48) |
| rucaparib | 0.8272 | 0.1886 (4.39) | 0.3320 (2.49) |
| talazoparib | 0.0009 | 0.0003 (3.32) | 0.0004 (2.32) |
| veliparib | 16.9900 | 5.3730 (3.16) | 8.0910 (2.10) |
| niraparib | 0.4010 | 0.1910 (2.10) | 0.1927 (2.08) |
| OVCAR-3 BRCA1 KD (cell viability) | |||
| talazoparib | 0.0058 | 0.0006 (10.24) | 0.0005 (11.81) |
| rucaparib | 2.4500 | 0.1345 (18.22) | 0.2293 (10.68) |
| niraparib | 3.6650 | 0.4730 (7.75) | 0.3468 (10.57) |
| olaparib | 2.9110 | 0.4229 (6.88) | 0.4687 (6.21) |
| veliparib | 20.5600 | 3.2850 (6.26) | 3.6540 (5.63) |
| A2780 BRCA1 KD (cell survival) | |||
| olaparib | 0.0275 | 0.0075 (3.67) | 0.0110 (2.50) |
| niraparib | 0.0471 | 0.0204 (2.30) | 0.0311 (1.51) |
| veliparib | 1.1726 | 0.5215 (2.25) | 0.8487 (1.38) |
| talazoparib | 0.0006 | 0.0003 (2.10) | 0.0004 (1.26) |
| rucaparib | 0.0283 | 0.0119 (2.38) | 0.0229 (1.24) |
| OVCAR-3 BRCA1 KD (cell survival) | |||
| rucaparib | 0.0173 | 0.0085 (2.04) | 0.0074 (2.33) |
| veliparib | 1.5195 | 1.3455 (1.13) | 0.7451 (2.04) |
| olaparib | 0.0089 | 0.0062 (1.43) | 0.0056 (1.59) |
| niraparib | 0.0319 | 0.0263 (1.22) | 0.0206 (1.55) |
| talazoparib | 0.0003 | 0.0003 (0.94) | 0.0003 (0.93) |
^ fold change is displayed in descending order for BRCA1 si#14; KD, knock-down; AS, AllStars non-silencing control.